A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
04 2019
Historique:
received: 23 08 2018
revised: 02 10 2018
accepted: 17 10 2018
pubmed: 6 11 2018
medline: 25 7 2020
entrez: 5 11 2018
Statut: ppublish

Résumé

Aspirin challenge and desensitization remains the criterion standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive. To provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in 1 day. Forty-four patients with a confirmed diagnosis of AERD, stable asthma, and baseline FEV Ninety-three percent of patients completed the challenge and desensitization in 1 day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over 2 days. One patient (2.3%) was discontinued from the protocol because of ongoing abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit, or hospitalization. Patients with AERD on a stable asthma regimen and with a baseline FEV

Sections du résumé

BACKGROUND
Aspirin challenge and desensitization remains the criterion standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive.
OBJECTIVE
To provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in 1 day.
METHODS
Forty-four patients with a confirmed diagnosis of AERD, stable asthma, and baseline FEV
RESULTS
Ninety-three percent of patients completed the challenge and desensitization in 1 day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over 2 days. One patient (2.3%) was discontinued from the protocol because of ongoing abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit, or hospitalization.
CONCLUSIONS
Patients with AERD on a stable asthma regimen and with a baseline FEV

Identifiants

pubmed: 30391549
pii: S2213-2198(18)30703-7
doi: 10.1016/j.jaip.2018.10.032
pmc: PMC6456426
mid: NIHMS1515230
pii:
doi:

Substances chimiques

Cyclooxygenase Inhibitors 0
Aspirin R16CO5Y76E

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1174-1180

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL128241
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007306
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI095219
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL111113
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI118804
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Références

Am J Cardiol. 1999 Aug 15;84(4):404-9
pubmed: 10468077
Clin Exp Allergy. 2005 Jun;35(6):717-22
pubmed: 15969660
Ann Allergy Asthma Immunol. 2006 Aug;97(2):190-5
pubmed: 16937750
J Allergy Clin Immunol. 2006 Oct;118(4):801-4
pubmed: 17030229
Ann Allergy Asthma Immunol. 2007 Feb;98(2):172-4
pubmed: 17304886
Ann Allergy. 1991 Dec;67(6):588-92
pubmed: 1750721
J Allergy Clin Immunol. 2009 Feb;123(2):406-10
pubmed: 19056109
Ann Allergy Asthma Immunol. 2010 Aug;105(2):130-5
pubmed: 20674823
Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273
pubmed: 20934625
J Allergy Clin Immunol Pract. 2015 Nov-Dec;3(6):926-31.e1
pubmed: 26282158
J Allergy Clin Immunol. 2019 Jan;143(1):316-324.e7
pubmed: 29890239
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1319-1321
pubmed: 30144584
J Allergy Clin Immunol. 1984 Oct;74(4 Pt 2):617-22
pubmed: 6436354

Auteurs

Geneva A DeGregorio (GA)

Department of Medicine, Brigham and Women's Hospital, Boston, Mass.

Joseph Singer (J)

Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and the Jeff and Penny Vinik Center, Boston, Mass.

Katherine N Cahill (KN)

Divison of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, Tenn.

Tanya Laidlaw (T)

Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and the Jeff and Penny Vinik Center, Boston, Mass. Electronic address: tlaidlaw@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH